MA53329A - Méthodes de traitement de l'épilepsie - Google Patents
Méthodes de traitement de l'épilepsieInfo
- Publication number
- MA53329A MA53329A MA053329A MA53329A MA53329A MA 53329 A MA53329 A MA 53329A MA 053329 A MA053329 A MA 053329A MA 53329 A MA53329 A MA 53329A MA 53329 A MA53329 A MA 53329A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment methods
- epilepsy treatment
- epilepsy
- methods
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53329A true MA53329A (fr) | 2022-03-02 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053329A MA53329A (fr) | 2018-07-27 | 2019-07-26 | Méthodes de traitement de l'épilepsie |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200030260A1 (enExample) |
| EP (1) | EP3829558B1 (enExample) |
| JP (1) | JP2021530541A (enExample) |
| KR (1) | KR20210061332A (enExample) |
| CN (1) | CN112930175A (enExample) |
| AU (1) | AU2019310600A1 (enExample) |
| BR (1) | BR112021001135A2 (enExample) |
| CA (1) | CA3106031A1 (enExample) |
| CL (1) | CL2021000196A1 (enExample) |
| CO (1) | CO2021002087A2 (enExample) |
| CR (1) | CR20210095A (enExample) |
| EA (1) | EA202190369A1 (enExample) |
| ES (1) | ES2988130T3 (enExample) |
| IL (1) | IL280128A (enExample) |
| MA (1) | MA53329A (enExample) |
| MX (1) | MX2021000987A (enExample) |
| PE (1) | PE20211065A1 (enExample) |
| PH (1) | PH12021550176A1 (enExample) |
| SG (1) | SG11202100682YA (enExample) |
| WO (1) | WO2020023923A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| CA3007286A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Fenfluramine compositions and methods of preparing the same |
| EP3393470B1 (en) | 2015-12-22 | 2021-01-20 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| MX2019001799A (es) | 2016-08-24 | 2019-06-13 | Zogenix International Ltd | Formulacion para inhibir la formacion de agonistas de 5-ht2b y metodos de utilizacion de la misma. |
| JP7383012B2 (ja) * | 2018-08-31 | 2023-11-17 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用 |
| EA202191079A1 (ru) | 2018-11-19 | 2021-09-20 | Зодженикс Интернэшнл Лимитед | Способы лечения синдрома ретта с применением фенфлурамина |
| EP3999570A1 (en) * | 2019-07-18 | 2022-05-25 | Basf Se | Allophanate based dispersing agent |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| EP4395753A4 (en) * | 2021-09-01 | 2025-05-07 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR104F (enExample) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| ES2157330T3 (es) * | 1994-06-03 | 2001-08-16 | Thejmde Trust | Composicion que comprende aril-alquil-amina meta substituida, usos terapeuticos y diagnosticos. |
| AU741482B2 (en) | 1997-05-07 | 2001-11-29 | Allergan Pharmaceuticals International Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| AU2016222804C1 (en) * | 2015-02-25 | 2021-10-14 | The Regents Of The University Of California | 5HT agonists for treating disorders |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 US US16/523,568 patent/US20200030260A1/en active Pending
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/en not_active Ceased
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/en active Active
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 CA CA3106031A patent/CA3106031A1/en active Pending
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021000196A1 (es) | 2021-12-31 |
| JP2021530541A (ja) | 2021-11-11 |
| ES2988130T3 (es) | 2024-11-19 |
| IL280128A (en) | 2021-03-01 |
| EP3829558C0 (en) | 2024-07-03 |
| BR112021001135A2 (pt) | 2021-04-20 |
| SG11202100682YA (en) | 2021-02-25 |
| EA202190369A1 (ru) | 2021-06-10 |
| WO2020023923A1 (en) | 2020-01-30 |
| PE20211065A1 (es) | 2021-06-09 |
| KR20210061332A (ko) | 2021-05-27 |
| AU2019310600A1 (en) | 2021-02-11 |
| MX2021000987A (es) | 2021-06-15 |
| CN112930175A (zh) | 2021-06-08 |
| EP3829558B1 (en) | 2024-07-03 |
| PH12021550176A1 (en) | 2021-10-11 |
| US20200030260A1 (en) | 2020-01-30 |
| EP3829558A1 (en) | 2021-06-09 |
| CO2021002087A2 (es) | 2021-04-30 |
| CA3106031A1 (en) | 2020-01-30 |
| CR20210095A (es) | 2021-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
| EP3813808A4 (en) | Methods of treating substance abuse | |
| EP3813647A4 (en) | MULTIMODAL STIMULATION FOR TREMOR TREATMENT | |
| EP3645121A4 (en) | METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS | |
| MA45192A (fr) | Traitement d'association | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| EP3813806A4 (en) | Methods of treating mitochondrial dysfunction | |
| EP3291815A4 (en) | METHOD FOR TREATING A NEURODEEGENERATIVE DISEASE | |
| EP3625971A4 (en) | SPATIAL AUDIO PROCESSING | |
| EP3946345A4 (en) | METHODS OF TREATMENT OF NEUROPATHIC PAIN | |
| EP3285776A4 (en) | METHOD FOR TREATING BACTERIAL INFECTIONS | |
| MA51678A (fr) | Méthodes de traitement de l'amyotrophie musculaire | |
| EP3589659A4 (en) | COMPOUNDS AND USES FOR TREATMENT OF CANCER | |
| MA47504A (fr) | Composés et méthodes de traitement de l'angiocholite biliaire primitive | |
| EP3606531A4 (en) | METHOD OF TREATMENT OF CANCER | |
| MA54860A (fr) | Méthodes de traitement du myélome multiple | |
| EP3751048A4 (en) | FIBER TREATMENT AGENT | |
| EP3393468A4 (en) | METHOD FOR TREATING AN IMMUNE WEAKNESS | |
| EP3454793A4 (en) | TREATMENT COILS FOR ANEURYSMS | |
| EP3383857A4 (en) | COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| EP3634422A4 (en) | Methods of treating leukodystrophies | |
| MA46353A (fr) | Méthodes de traitement de l'infertilité féminine | |
| EP3787625A4 (en) | METHODS OF TREATMENT OF CANCER | |
| EP3599983A4 (en) | ENDOSCOPES AND TREATMENT PROCEDURES | |
| EP3852816A4 (en) | METHODS OF TREATMENT OF CANCER |